Alivus Life Sciences Ltd ALIVUS
NSE · India · Health Technology
INR 1,380.00+0.70 (+0.05%)
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Global markets are being shaken by rising US Treasury yields, firm Fed hike expectations, expensive crude and a softer rupee, and that mix is hitting Indian equities hard while quietly reshaping the opportunity set. Currency pressure can hurt importers but often helps exporters with foreign-currency revenue. This article walks through three rupee-sensitive Indian exporters exposed to the current news flow, helping you evaluate where risk and potential reward now sit. The stocks highlighted...
Alivus Life Sciences Ltd (BOM:543322) reports robust 36.6% EBITDA margin and 26.5% non-GPL growth, while navigating GPL decline and geopolitical risks.
Alivus Life Sciences Ltd (BOM:543322) reports historic EBITDA margins and robust portfolio expansion, while navigating external pressures and operational setbacks.
Alivus Life Sciences Ltd (BOM:543322) reports a robust 16% revenue growth and improved EBITDA margins, while addressing challenges in the GPL and CDMO segments.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.